Skip to main content

Advertisement

Table 4 Incident rates and hazard ratios (HRs) for association of fracture with methotrexate and glucocorticoid use among those with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA)

From: Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study

Variables Number of patients Number with fracture Rate per 10,000 person-years (95% CI) Unadjusted HR (95% CI) Adjusted HR (95% CI)a
PMR
Methotrexate
  No 11,430 1614 151.32 (144.11–158.89) Reference Reference
  Yes 706 75 101.03 (80.57–126.69) 0.65 (0.52–0.83) 0.96 (0.75–1.21)
Glucocorticoid average daily dose (quintiles)
  Quintile 1 (1–4.9 mg) 2148 281 135.72 (120.74–152.55) Reference Reference
  Quintile 2 (4.9–6.1 mg) 2148 286 139.86 (124.56–157.05) 1.03 (0.88–1.22) 1.12 (0.95–1.32)
  Quintile 3 (6.1–7.5 mg) 2147 291 141.52 (126.16–158.75) 1.04 (0.88–1.23) 1.16 (0.99–1.37)
  Quintile 4 (7.5–10.0 mg) 2148 283 141.32 (125.78–158.78) 1.04 (0.88–1.23) 1.27 (1.08–1.50)
  Quintile 5 (10.0–73.3 mg) 2147 367 196.70 (177.57–217.89) 1.46 (1.25–1.71) 1.85 (1.59–2.17)
GCA
Methotrexate
  No 2551 353 147.51 (132.90–163.73) Reference Reference
  Yes 122 18 140.38 (88.45–222.82) 0.94 (0.58–1.50) 1.36 (0.84–2.19)
Glucocorticoid average daily dose (quintiles)
  Quintile 1 (1.1–5.7 mg) 447 52 118.06 (80.96–154.93) Reference Reference
  Quintile 2 (5.7–7.5 mg) 446 63 147.64 (115.33–188.99) 1.26 (0.87–1.81) 1.51 (1.05–2.19)
  Quintile 3 (7.5–9.8 mg) 447 59 138.05 (106.85–178.18) 1.17 (0.81–1.70) 1.46 (1.00–2.12)
  Quintile 4 (9.8–13.5 mg) 446 57 138.33 (106.70–179.34) 1.18 (0.81–1.71) 1.58 (1.08–2.30)
  Quintile 5 (13.5–83.9 mg) 446 72 181.18 (143.81–228.25) 1.54 (1.08–2.20) 2.09 (1.46–2.99)
  1. aAdjusted for confounding factors which affected the HR > 10%, from age, sex, BMI, alcohol consumption, smoking status, bisphosphonate use, Charlson comorbidity index and PPI use. Patients not on glucocorticoids were excluded from this analysis